Precisely Strengthens its Location Intelligence Offering Through the Acquisition of Transerve
31.1.2023 16:00:00 EET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced it has acquired Transerve, a location intelligence and data provider with expertise in spatial data handling, processing and analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230131005192/en/
Precisely, the global leader in data integrity, announces its acquisition of Transerve, a location intelligence and data provider with expertise in spatial data handling, processing and analysis. (Graphic: Business Wire)
Transerve, headquartered in the Goa region of India, provides a cloud-native location intelligence solution and data library with curated datasets, enabling fast time to value with a nimble spatial analytics SaaS solution for enterprise and midsize companies. Transerve incorporates a simple, yet powerful, combination of geospatial artificial intelligence (AI), machine learning (ML) and geoprocessing that supports data democratization by making location analysis and data enrichment available to data-centric employees without requiring the need for geographic information system (GIS) expertise.
Customers in industries such as banking, insurance, telco, government, retail, and real estate will benefit from a more complete and contextual picture of data that informs decision-making including, but not limited to, market potential, risk assessment, site selection and optimization, and more. Transerve allows users to enrich data with high-quality, curated spatial datasets and easily create and share web-based maps.
“In the past, deriving insights from location and creating visualizations was the domain of GIS specialists,” said Clarence Hempfield, Senior Vice President of Product Management, Location Intelligence at Precisely. “With the acquisition of Transerve, Precisely adds new SaaS location intelligence capabilities to its portfolio of data integrity software and data. This allows users, without specialized knowledge or skills, to leverage location data and analytics and derive new insights about their business.”
“We've been on a mission to make spatial data easier to access, understand and take action on for businesses," said Ashwanii Rawat, CEO and Co-Founder at Transerve. "We're delighted to be joining Precisely who shares this passion for location intelligence and bringing the power of location data to everyday data roles to make an impact for the companies we serve and broaden our impact in the market.”
This acquisition follows the launch of the Precisely Data Integrity Suite, an integrated, interoperable suite designed to deliver accurate, consistent, contextualized data to businesses. Learn more about the Data Integrity Suite.
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
About Transerve
Founded in 2009, Transerve is a location intelligence company based in Panaji, India that uses geospatial technology to enable digital transformation and effective decision-making. It helps in deploying customized applications for asset tracking and mapping, monitoring of projects, spatial data collection with geo-tagged pictures and videos, and to share maps with key stakeholders or the public. Learn more at www.transerve.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230131005192/en/
Contact information
Press
Emma Forrest
press@precisely.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom